Topcon Healthcare Acquires RetInSight to Expand AI-Driven Retinal Imaging Capabilities

Topcon Healthcare 收购 RetInSight 以扩展人工智能驱动的视网膜成像能力

May 06, 2025

2025年5月6日

Topcon Healthcare has announced its acquisition of RetInSight, a Vienna, Austria-based AI company specializing in ophthalmic imaging analysis. The acquisition advances Topcon Healthcare’s strategic vision of “Healthcare from the Eye”, aiming to improve global access to intelligent diagnostics that enhance eye care delivery, reduce healthcare costs, and improve clinical outcomes..

Topcon Healthcare 宣布收购了总部位于奥地利维也纳的视网膜影像分析AI公司 RetInSight。此次收购推进了 Topcon Healthcare 的“从眼睛开始的医疗保健”战略愿景，旨在改善全球对智能诊断的获取，提升眼科护理服务，降低医疗成本，并改善临床结果。

AI Algorithms Supporting Early Detection and Monitoring of Retinal Diseases

支持视网膜疾病早期检测和监测的人工智能算法

RetInSight’s AI platform analyzes optical coherence tomography (OCT) images acquired during routine clinical care. Its suite of algorithms is designed to detect and monitor major retinal diseases, including:

RetInSight的人工智能平台分析在常规临床护理期间获取的光学相干断层扫描（OCT）图像。其算法套件旨在检测和监测主要的视网膜疾病，包括：

•

•

Geographic atrophy

地理性萎缩

•

•

Wet age-related macular degeneration (AMD)

湿性年龄相关性黄斑变性 (AMD)

•

•

Diabetic macular edema (DME)

糖尿病性黄斑水肿 (DME)

•

•

Retinal vein occlusion (RVO)

视网膜静脉阻塞 (RVO)

These tools support early intervention and personalized treatment planning, especially vital in aging populations where retinal conditions are increasingly prevalent.

这些工具支持早期干预和个性化治疗规划，尤其是在视网膜疾病日益普遍的老龄化人口中尤为重要。

Origin and Interoperability of RetInSight Technology

RetInSight技术的起源与互操作性

RetInSight’s platform originated from research conducted at the Medical University of Vienna’s Department of Ophthalmology and Optometry, led by Prof. Dr. Ursula Schmidt-Erfurth. The technology is already commercialized across Europe and is vendor-inclusive, meaning it supports interoperability with various OCT systems..

RetInSight的平台源自维也纳医科大学眼科与视光学系Prof. Dr. Ursula Schmidt-Erfurth领导的研究。该技术已经在欧洲广泛商业化，并且是供应商包容性的，意味着它支持与各种OCT系统的互操作性。

Leadership Commentary on Strategic Synergies

关于战略协同的领导评论

Prof. Hans Peter Schwarz, Chairman of the Board at RetInSight, expressed enthusiasm about the acquisition:

RetInSight董事会主席汉斯·彼得·施瓦茨教授对此次收购表示热情：

“With Topcon Healthcare’s infrastructure, we can scale reliable and affordable AI software globally. This partnership supports clinical care, drug discovery, and therapeutic innovation worldwide.”

“通过拓普康医疗的基础设施，我们能够在全球范围内扩展可靠且价格合理的AI软件。这一合作伙伴关系支持全球的临床护理、药物发现和治疗创新。”

Ali Tafreshi, CEO and President of Topcon Healthcare, emphasized the strategic value of RetInSight’s expertise:

拓普康医疗公司首席执行官兼总裁阿里·塔弗雷什强调了RetInSight专业知识的战略价值：

“RetInSight’s OCT-based AI expertise will help our global network of partners rapidly deploy innovations. Integrated with our Harmony vendor-inclusive digital information system, we’re delivering clinical decision support and a scalable ecosystem for AI deployment.”

“RetInSight基于OCT的AI专业知识将帮助我们的全球合作伙伴网络快速部署创新。与我们的Harmony供应商包容性数字信息系统相结合，我们正在提供临床决策支持和可扩展的AI部署生态系统。”

Broader Implications for Drug Development and Regulatory Progress

药物开发和监管进展的更广泛影响

RetInSight’s AI algorithms are already used in pharmaceutical clinical trials and contribute to AI-powered drug development and regulatory pathways, including ongoing work to advance FDA clearances for U.S. indications.

RetInSight的人工智能算法已应用于制药临床试验，并推动了人工智能驱动的药物开发和监管路径，包括正在进行的工作以推进美国适应症的FDA审批。

Dr. Amir Sadeghipour, Managing Director of RetInSight, added:

视网膜洞察公司总经理阿米尔·萨德吉普尔博士补充道：

“Together, we’re enabling seamless patient monitoring across the eye care continuum. This collaboration brings intelligent care to patients anywhere.”

“我们正在整个眼科护理过程中实现无缝的患者监测。这项合作可以为任何地方的患者带来智能化护理。”